Coagulometers

History

2024

Sales of hemostasis analyzers in the world for the year reached $3.69 billion

At the end of 2024, the costs on the global market for hemostasis analyzers amounted to $3.69 billion. More than a third of this amount was provided by the North American region. Industry trends are addressed in a Fortune Business Insights story published in mid-November 2025.

A hemostasis analyzer (or coagulometer) is a medical laboratory device that measures blood clotting parameters to diagnose hemostasis disorders, monitor anticoagulant therapy, etc. Such devices help to detect clotting disorders associated with thrombosis, bleeding and liver disease (hepatology). Coagulometers are used in preparation for operations or as part of the treatment of cardiovascular diseases, as well as for the diagnosis and therapy of disorders of the blood clotting system in children and the detection of genetic abnormalities. Blood clotting tests are often done during pregnancy to monitor the condition of the mother and fetus.

The study says that the expansion of the market in question is facilitated by an increase in the prevalence of diseases associated with impaired blood clotting, such as hemophilia. Aging populations and unhealthy lifestyles exacerbate the problem. In this regard, hospitals, laboratories and other medical institutions are increasingly purchasing coagulation analyzers for accurate and rapid diagnosis, which is critical to ensuring effective treatment of patients. Modern automatic devices allow you to obtain reliable results, excluding the influence of the human factor. High-performance models can perform up to several hundred tests per hour, which is important for laboratories with a large patient flow. Some devices are capable of performing both standard and chromogenic and immunological tests.

Another driver of the industry is the development of personalized medicine. Individually selected anticoagulant therapy (e.g. warfarin-based) requires continuous coagulation monitoring, which stimulates the demand for coagulometers. The integration of artificial intelligence allows the analysis of historical data and test results to form personalized treatment plans and predict the condition of a particular patient.

Technological advances have a positive impact on the market. Developers are constantly improving the characteristics of the equipment and expanding their capabilities. Integration with cloud platforms is observed to ensure uninterrupted communication between doctors and patients.

The authors of the study segment the industry into coagulometers and consumables themselves. The latter provided more than 60% of revenue in 2024. By design, optical, mechanical, ultrasonic and other devices are distinguished. The largest share was in the optical detection sector. Geographically, North America leads with 35.5%, or $1.31 billion. Major industry players on a global scale are:

• Siemens Healthineers AG;
• Sysmex;
• Hoffmann-La Roche;
• Werfen;
• Helena Laboratories Corporation;
• Beckman Coulter;
• Meril Life Sciences;
• Horiba;
• Biolabo S.A.S;
• Diagon.

In 2025, the coagulometer market size is expected to reach $3.9 billion. The United States will have $1.18 billion, Europe - $1.16 billion, Asia-Pacific - $1.1 billion. Fortune Business Insights analysts predict that in the future, the CAGR will be at 6%. Thus, by 2032, costs may increase to $5.87 billion.^[1]

Sales of coagulometers in the world reached $1.51 billion

In 2024, the global coagulometer market reached $1.51 billion. More than 40% of global spending was in the North American region. This is stated in a study by Fortune Business Insights, the results of which were published on July 30, 2025.

Coagulometer - a medical device designed to study the hemostasis system. Such devices are used, in particular, to detect blood clotting pathologies and disorders in the functioning of the anticoagulant system, as well as in the treatment of heart diseases, cirrhosis of the liver and hepatitis. In addition, coagulometers are used to assess the effectiveness of anticoagulant therapy - this is a set of therapeutic measures aimed at inhibiting the activity of blood clotting and preventing the formation of blood clots. Anticoagulants are used in myocardial infarction, pulmonary embolism, thrombotic and embolic strokes, thrombophlebitis.

𝓲

Фото: Freepik

One of the drivers of the market in question, analysts call the increase in the prevalence of cardiovascular diseases (CVD). According to the World Health Organization, CVDs are the leading cause of death worldwide, with 17.9 million deaths each year. More than four in five CVD deaths occur as a result of heart attack and stroke, with a third of these cases being premature and reported among people under the age of 70. Most cardiovascular diseases can be prevented by affecting behavioral and environmental risk factors such as tobacco use, unhealthy diet and obesity, lack of physical activity, harmful alcohol use, and air pollution. Some CVDs, such as heart failure and congenital heart disease, are directly related to bleeding disorders: against the background of an increase in the number of such diagnoses, the demand for coagulometers is growing.

Technological advances have a positive impact on the industry. The devices are becoming more compact and convenient to use. Integration with digital medical platforms enables real-time data sharing and remote patient follow-up.

The study authors also point to a number of deterrents. One of them is the high price. For example, the cost of analyzers for determining INR (international normalized ratio - a study aimed at determining the time required for blood clotting) can reach $3,000. Another problem analysts call the lack of standardization in the definition of INR. Due to differences in the composition of reagents, calibration methods and sensitivity of instruments, inconsistencies may occur, leading to misinterpretation of the results: this increases the risk of bleeding or thromboembolic complications.

Geographically, North America led in 2024 with a share of about 41.1%, or $0.62 billion. The Asia-Pacific region shows the highest growth rate, due to the increase in the number of patients with CVD. Globally, significant players are named:

• Werfen;
• Helena Diagnostics;
• Abbott;
• Hoffmann-La Roche;
• Siemens Healthineers;
• Koninklijke Philips;
• Horiba;
• Sysmex.

In 2025, the global coagulometer market is expected to reach $1.61 billion. Fortune Business Insights forecasts a CAGR of 7.2% going forward. Thus, by 2032, costs may increase to $2.62 billion.^[2]

Notes